Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke's B colorectal cancer patients: How much evidence is enough?

Annals of Oncology

Volumn 14, Issue 7, 2003, Pages 1026-1038

  Graziano, Francesco ^a   Cascinu, S ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b Ospedale di Parma   (Italy)

Author keywords

Colorectal cancer; Dukes' B; Prognosis; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLINE; EPITOPE; FLUOROURACIL; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; PLASMINOGEN; PROTEIN BCL 2; PROTEIN P53; RALTITREXED; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DNA REPAIR; EVIDENCE BASED MEDICINE; GENE DELETION; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; ONCOGENE C ERB; ONCOGENE K RAS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

CELL DIVISION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA REPAIR; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PATIENT CARE PLANNING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0043203055     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg284     Document Type: Review

References (139)

1. Mcdonald JS. Adjuvant therapy of colorectal cancer. CA Cancer J Clin 1999; 49: 202-219.
2. O'Connell MJ, Schaid DJ, Ganju V et al. Current status of adjuvant therapy of colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 1992; 70 (Suppl): 1732-1739.
3. McLeod HL, Murray GI. Tumor markers of prognosis in colorectal cancer. Br J Cancer 1999; 79: 191-203.
4. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-2877.
5. Altman DG. Systematic reviews in health care. Systematic reviews of evaluations of prognostic variables. Br Med J 2001; 323: 224-228.
6. Sun XF, Carstensen JM, Stal O et al. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2, p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int J Cancer 1996; 69: 5-8.
7. Jansson A, Sun XF. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 1997; 105: 730-734.
8. Allegra CJ, Parr AL, Wold LE et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1735-1743.
9. Palmqvist R, Sellberg P, Oberg A et al. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 1999; 79: 577-581.
10. Guerra A, Borda F, Javier Jimenez F et al. Multivariate analysis of prognostic factors in resected colorectal cancer: a new prognostic index. Eur J Gastroenterol Hepatol 1998; 10: 51-58.
11. Chen YT, Henk MJ, Carney KJ et al. Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index. J Gastrointest Surg 1997; 1: 266-273.
12. Bhatavdekar JM, Patel DD, Chikhlikar PR et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001; 44: 523-533.
13. Buglioni S, D'Agnano I, Cosimelli M et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role pf p53 and bcl-2. Int J Cancer 1999; 84: 545-552.
14. Handa K, Yamakawa M, Takeda H et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999; 84: 225-233.
15. Tenjo T, Toyoda M, Okuda J et al. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000; 58: 45-51.
16. Folkman J. Tumor angiogenesis and tissue factors. Nat Med 1996; 2: 167-168.
17. Giatromanolaki A, Stathopoulos GP, Tsiobanou E et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999; 86: 1421-1425.
18. Vermeulen PB, Van den Eynden GG, Huget P et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999; 79: 316-322.
19. Frank RE, Saclarides TJ, Leurgans S et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995; 222: 695-699.
20. Banner BF, Whitehouse R, Baker SP, Swanson RS. Tumor angiogenesis in stage II colorectal carcinoma: association with survival. Am J Clin Pathol 1998; 109: 733-737.
21. Takahashi Y, Tucker SL, Kitadai Y et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132: 541-546.
22. Lindmark G, Gerdin B, Sundberg C et al. Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol 1996; 14: 461-466.
23. Cascinu S, Staccioli MP, Gasparini G et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6: 2803-2807.
24. Tanigawa N, Amaya H, Matsumura M et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57: 1043-1046.
25. Takebayashi Y, Aklyama S, Yamada K et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-231.
26. Galindo Gallego M, Fernandez Acenero MJ, Sanz Ortega J, Aljama A. Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer 2000; 36: 55-60.
27. Maeda K, Nishiguchi Y, Yashiro M et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000; 5: 373-378.
28. Kang SM, Maeda K, Chung YS. Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep 1997; 4: 381-384.
29. Amaya H, Tanigawa N, Lu C et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial growth factor expression in human colorectal cancer. Cancer Lett 1997; 119: 227-235.
30. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 748-753.
31. Ishigami SI, Arii S, Furutani M et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-1384.
32. Tokunaga T, Oshika Y, Abe Y et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998; 77: 998-1002.
33. Yang JL, Seetoo D, Wang Y et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000; 5: 431-439.
34. Abe J, Urano T, Konno H et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999; 12: 2602-2611.
35. Fujii T, Obara T, Tanno S et al. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology 1999; 28: 2299-2308.
36. Skelly MM, Troy A, Duffy MJ et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997; 10: 1837-1840.
37. Sato T, Nishimura G, Yonemura Y et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 1995; 4: 347-352.
38. Ganesh S, Sier CF, Griffioen G et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 15: 4065-4071.
39. Raigoso P, Junco A, Andicoechea A et al. Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. Int J Biol Markers 2000; 15: 44-50.
40. Stephens RW, Nielsen HJ, Christensen IJ et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 10: 869-874.
41. Ganesh S, Sier CF, Heerding MM et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997; 12: 1793-1801.
42. Mulcahy HE, Duffy MJ, Gibbons D et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 8922: 583-584.
43. Masaki T, Matsuoka H, Sugiyama M et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001; 84: 1317-1321.
44. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo 2000; 14: 659-666.
45. Oberg A, Hoyhtya M, Tavelin B et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20: 1085-1091.
46. Zeng ZS, Cohen AM, Zhang ZF et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995; 8: 899-906.
47. Ring P, Johansson K, Hoyhtya M et al. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer: a predictor of tumour stage. Br J Cancer 1997; 6: 805-811.
48. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 12: 3133-3140.
49. Murray GI, Duncan ME, O'Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 4: 461-462.
50. Liabakk NB, Talbot I, Smith RA et al. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-196.
51. Holten-Andersen MN, Stephens RW, Nielsen HJ et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 11:4292-4299.
52. Mysliwiec AG, Ornstein DL. Matrix metalloproteinases in colorectal cancer. Clin Colorectal Cancer 2002; 1: 208-219.
53. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1404-1412.
54. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-2647.
55. Takenoue T, Nagawa H, Matsuda K et al. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000; 7: 193-198.
56. Edler D, Hallstrom M, Johnston PG et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000; 6: 1378-1384.
57. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998; 4: 1227-1234.
58. Edler D, Kresser U, Ragnhammar P et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000; 6: 488-489.
59. Yamachika T, Nakanishi H, Inada K et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998; 82: 70-77.
60. Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721-1728.
61. Kralovanszky J, Koves I, Orosz Z et al. Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. Oncology 2002; 2: 167-174.
62. Kornmann M, Link KH, Galuba I et al. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 2002; 6: 331-337.
63. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455.
64. Baas IO, Mulder JW, Offerhaus GJ et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
65. Børresen-Dale AL, Lothe RA, Meling GI et al. TP53 and long-term prognosis in colorectal cancer: mutations in the L3Zinc-binding domain predict poor survival. Clin Cancer Res 1998; 4: 203-210.
66. Forslund A, Lonnroth C, Andersson M et al. Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma. J Clin Oncol 2001; 19: 2829-2836.
67. Petersen S, Thames HD, Nieder C et al. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 2001; 44: 322-333.
68. Gervaz P, Bouzourene H, Cerottini JP et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001; 44: 364-372.
69. Buglioni S, D'Agnano I, Vaselli S et al. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant chemotherapy. Am J Clin Pathol 2001; 116: 360-368.
70. Soong R, Powell B, Elsaleh H et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence on tumor site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000; 36: 2053-2060.
71. Bouzourene H, Gervaz P, Cerottini JP et al. p53 and K-ras as prognostic factors for Dukes'stage B colorectal cancer. Eur J Cancer 2000; 36: 1008-1015.
72. Gallego MG, Acenero MJ, Ortega S et al. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 2000; 43: 971-975.
73. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA et al. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 2000; 88: 1814-1819.
74. Schwandner O, Schiedeck THK, Bruch H et al. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000; 36: 348-356.
75. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
76. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study. J Natl Cancer Inst 1998; 90: 675-684.
77. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. Br J Cancer 2001; 85: 692-696.
78. Bazan V, Migliavacca M, Zanna I et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438-1446.
79. Font A, Abad A, Monzo M et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001; 44: 549-557.
80. Esteller M, Gonzalez S, Risques RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304.
81. Karelia NH, Patel DD, Desai NS et al. Prognostic significance of DNA aneuploidy and p21 ras oncoprotein expression in colorectal cancer and their role in the determination of treatment modalities. Int J Biol Markers 2001; 16: 97-104.
82. Zirbes TK, Baldus SE, Moenig SP et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000; 89: 14-18.
83. Sun XF, Ekberg H, Zhang H et al. Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma. APMIS 1998; 106: 657-664.
84. Fearon ER, Cho KR, Nigro JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-58.
85. Turley H, Pezzella F, Kocialkowski S et al. The distribution of the deleted in colon cancer (DCC) protein in human tissues. Cancer Res 1995; 55: 5628-5631.
86. Shibata D, Reale MA, Lavin P et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335: 1727-1732.
87. Jernvall P, Makinen MJ, Karttunen TJ et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999; 79: 903-908.
88. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221.
89. Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16: 427-433.
90. Lanza G, Matteuzzi M, Gafa R et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79: 390-395.
91. Carethers JM, Hawn MT, Greenson JK et al. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114: 1188-1195.
92. Martinez-Lopez E, Abad A, Font A et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998; 114: 1180-1187.
93. Sun XF, Rutten S, Zhang H, Nordenskjold B. Expression of the deleted in colorectal gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 1999; 17: 1745-1750.
94. Reymond MA, Dworak O, Remke S et al. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 1998; 41: 755-760.
95. Laurent-Puig P, Olschwang S, Delattre O et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102: 1136-1141.
96. Dix BR, Robbins P, Soong R et al. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59: 747-751.
97. Ko JM, Cheung MH, Kwan MW et al. Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma. Int J Cancer 1999; 84: 404-409.
98. Watanabe N, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
99. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic tumorigenesis. Nature 1993; 363: 558-561.
100. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
101. Hoang JM, Cottu P, Thuille B et al. BAT-26 and indicator of the replication error phenotype in colorectal cancer and cell lines. Cancer Res 1997; 300-303.
102. Marcus VA, Madlensky L, Gryfe R et al. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 1999; 23: 1248-1255.
103. Johannsdottir JT, Bergthorsson JT, Gretarsdottir S et al. Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 1999; 19: 1821-1826.
104. Farrington SM, McKinley AJ, Cunningham C et al. Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int J Cancer 2002; 98: 844-850.
105. Salahshor S, Kressner U, Fisher H et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 1999; 81: 190-193.
106. Feeley KM, Fullard JF, Heneghan MA et al. Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 1999; 188: 14-17.
107. Curran B, Lenehan K, Mulcahy H et al. Replication error phenotype, clinicopathological variables and patient, outcome in Dukes' B stage II (T3N0M0) colorectal cancer. Gut 2000; 46: 200-204.
108. Gervaz P, Cerottini JP, Bouzourene H et al. Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery 2002; 131: 190-197.
109. Bubb YJ, Curtis LJ, Cunningham C et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996; 12: 2641-2649.
110. Lukish JR, Muro K, DeNobile J et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer Ann Surg 1998; 227: 51-56.
111. Lothe RA, Peltomaki P, Meling GI et al. Genomic instability in colorectal cancer: relationships to clinicopathologic variables and family history. Cancer Res 1993; 53: 5849-5852.
112. Colombino M, Cossu A, Manca A et al. Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. Ann Oncol 2002; 13: 1447-1453.
113. Choi SW, Lee KJ, Bae YA et al. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 2002; 8: 2311-2312.
114. Michael-Robinson JM, Reid LE, Purdie DM et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res 2001; 7: 2347-2356.
115. Ward R, Meagher A, Tomlinson I et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001; 48: 821-829.
116. Hawkins NJ, Tomlinson I, Meagher A, Ward RL. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer 2001; 84: 232-236.
117. Gafa R, Maestri I, Matteuzzi M et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000; 89: 2025-2037.
118. Massa MJ, Iniesta P, Gonzalez-Quevedo R et al. Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer. Eur J Cancer 1999; 35: 1676-1682.
119. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819.
120. Guidoboni M, Gafa R, Viel A et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159: 297-304.
121. Samowitz WS, Curtin K, Ma KN et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917-923.
122. Kruschewski M, Noske A, Haier J et al. Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? Clin Exp Metastasis 2002; 19: 71-77.
123. Perrin J, Gouvernet J, Parriaux D et al. MSH2 and MLH1 immunodetection and the prognosis of colon cancer. Int J Oncol 2001; 19: 891-895.
124. Halling KC, French AJ, McDonnell SK et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295-1303.
125. Gryfe R, Kim H, Hsieh ETK et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
126. Gonzalez-Garcia I, Moreno V, Navarro M et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 2000; 92: 544-549.
127. Nicholl ID, Dunlop MG. Molecular markers of prognosis in colorectal cancer. J Natl Cancer Inst 1999; 91: 1267-1269.
128. Watanabe T, Chung DC. Molecular prognostic markers and colorectal cancer: the search goes on. Gastroenterology 1998; 114: 1330-1332.
129. Barozzi C, Ravaioli M, D'Errico A et al. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002; 94: 647-657.
130. Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed c-erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002; 38: 1065-1071.
131. Vizoso F, Vilar C, Rodriguez JC et al. C-erbB-2 oncoprotein content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. Int J Surg Investig 2000; 1: 483-493.
132. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4): 9-15.
133. Bisgard ML, Jager AC, Dalgaard P et al. Allelic loss of chromosome 2p21-16.3 is associated with reduced survival in sporadic colorectal cancer. Scand J Gastroenterol 2001; 36: 405-409.
134. Iniesta P, Massa MJ, Gonzalez-Quevedo R et al. Loss of heterozygosity at 3p23 is correlated with poor survival in patients with colorectal carcinoma. Cancer 2000; 89: 1220-1227.
135. Arribas R, Ribas M, Risques RA et al. Prospective assessment of allelic losses at 4p14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival. Clin Cancer Res 1999; 5: 3454-3459.
136. Gebert J, Sun M, Ridder R et al. Molecular profiling of sporadic colorectal tumors by microsatellite analysis. Int J Oncol 2000; 16: 169-179.
137. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002; 29: 222-230.
138. Mamounas EP. Adjuvant chemotherapy for stage II colon cancer: the time has come. Eur J Surg Oncol 2000; 8: 725-729.
139. Wein A, Hahn EG, Merkel S, Hohenberger W. Adjuvant chemotherapy for stage II (Dukes' B) colon cancer: too early for routine use. Eur J Surg Oncol 2000; 8: 730-732.